PMID- 23749887
OWN - NLM
STAT- MEDLINE
DCOM- 20130813
LR  - 20211021
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 33
IP  - 6
DP  - 2013 Jun
TI  - Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 
      human ovarian carcinoma.
PG  - 2391-400
AB  - BACKGROUND: Ovarian cancer is commonly treated with cisplatin/paclitaxel but many 
      tumors become resistant. Acetaminophen reduced glutathione and enhanced 
      chemotherapy efficacy in hepatic cancer treatment. The objective of this study 
      was to examine if acetaminophen enhances the cytotoxicity of cisplatin/paclitaxel 
      in ovarian cancer. MATERIALS AND METHODS: SKOV3 human ovarian carcinoma cells in 
      vitro and a subcutaneous tumor nude rat model were used and treated with 
      cisplatin/paclitaxel with or without acetaminophen. RESULTS: In vitro, 
      acetaminophen enhanced apoptosis induced by cisplatin and paclitaxel with similar 
      effects on glutathione, reactive oxygen species and mitochondrial membrane 
      potential, but different effects on nuclear factor erythroid 2-related factor 2 
      (NRF2) translocation. In vivo, acetaminophen was uniformly distributed in tissues 
      and significantly reduced hepatic glutathione. Acetaminophen enhanced the 
      cisplatin chemotherapeutic effect by reducing tumor recurrence. CONCLUSION: Our 
      results suggest that acetaminophen as a chemoenhancing adjuvant could improve the 
      efficacy of cisplatin and paclitaxel in treating patients with ovarian carcinoma 
      and other tumor types.
FAU - Wu, Ying-Jen Jeffrey
AU  - Wu YJ
AD  - Department of Neurology, Oregon Health and Sciences University, Portland, OR 
      97239, USA.
FAU - Neuwelt, Alexander J
AU  - Neuwelt AJ
FAU - Muldoon, Leslie L
AU  - Muldoon LL
FAU - Neuwelt, Edward A
AU  - Neuwelt EA
LA  - eng
GR  - R01 NS053468/NS/NINDS NIH HHS/United States
GR  - CA137488/CA/NCI NIH HHS/United States
GR  - R37 NS044687/NS/NINDS NIH HHS/United States
GR  - NS44687/NS/NINDS NIH HHS/United States
GR  - NS053468/NS/NINDS NIH HHS/United States
GR  - R01 NS044687/NS/NINDS NIH HHS/United States
GR  - R01 CA137488/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (Reactive Oxygen Species)
RN  - 362O9ITL9D (Acetaminophen)
RN  - GAN16C9B8O (Glutathione)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Acetaminophen/*pharmacology/therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Cisplatin/*pharmacology/therapeutic use
MH  - Female
MH  - Glutathione/metabolism
MH  - Humans
MH  - Membrane Potential, Mitochondrial/drug effects
MH  - NF-E2-Related Factor 2/metabolism
MH  - Neoplasm Transplantation
MH  - Ovarian Neoplasms/*drug therapy
MH  - Paclitaxel/*pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Nude
MH  - Reactive Oxygen Species
MH  - Xenograft Model Antitumor Assays
PMC - PMC3709593
MID - NIHMS491221
OTO - NOTNLM
OT  - Acetaminophen
OT  - SKOV3 cells
OT  - chemo-enhancement
OT  - cisplatin
OT  - glutathione
OT  - ovarian cancer
EDAT- 2013/06/12 06:00
MHDA- 2013/08/14 06:00
PMCR- 2014/06/01
CRDT- 2013/06/11 06:00
PHST- 2013/06/11 06:00 [entrez]
PHST- 2013/06/12 06:00 [pubmed]
PHST- 2013/08/14 06:00 [medline]
PHST- 2014/06/01 00:00 [pmc-release]
AID - 33/6/2391 [pii]
PST - ppublish
SO  - Anticancer Res. 2013 Jun;33(6):2391-400.